Efficacy, safety, and adverse effects of finasteride and dutasteride in treating benign prostatic hyperplasia: A retrospective cohort study
Abstract
Background and objective: Symptomatic benign prostatic hyperplasia (BPH) results in several symptoms including the lower urinary tract symptoms. Consequently, BPH may affect the bladder and finally the kidneys. There are various pharmacological options for the treatment of BPH including 5-Alpha Reductase Inhibitors (5-ARIs) (finasteride or dutasteride). Recent researchers have demonstrated that using 5-ARIs for treating BPH may have unfavorable adverse effects. Therefore, this study aimed to compare finasteride and dutasteride in terms of their efficacy, safety, and adverse effects.
Methods: This retrospective cohort study included 170 patients, 77 patients who received finasteride and 93 patients who received dutasteride, the data obtained retrospectively from medical databases and file sheets were reviewed and selected according to inclusion and exclusion criteria followed by the comparison between two groups regarding baseline characteristics, prostate volume and the incidence of adverse effects.
Results: Similarity observed between two groups at baseline characteristics. Statistically, no significant differences were identified between dutasteride and finasteride in the reduction of prostate volume. However, dutasteride and finasteride significantly reduced prostate volume at 1-year follow-up. No significant differences were observed between two agents regarding the incidence of adverse effects.
Conclusion: Finasteride and dutasteride improved lower urinary tract…
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.